Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 138 | GlobeNewswire (Europe) | DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
Mi | Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates | 3 | Insider Monkey | ||
Di | Taysha reports progress in Rett syndrome gene therapy trials | 1 | Investing.com | ||
TAYSHA GENE THERAPIES Aktie jetzt für 0€ handeln | |||||
Di | Taysha berichtet über Fortschritte bei Gentherapiestudien für Rett-Syndrom | 5 | Investing.com Deutsch | ||
Di | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program | 3 | GlobeNewswire (USA) | ||
Di | Canaccord Genuity raises Taysha Gene Therapies stock price target | 3 | Investing.com | ||
Mo | Where Taysha Gene Therapies Stands With Analysts | 1 | Benzinga.com | ||
29.05. | Why Is Taysha Gene Therapies Stock Trading Higher On Thursday? | 1 | Benzinga.com | ||
29.05. | Cantor Fitzgerald maintains $7 target on Taysha Gene shares | 1 | Investing.com | ||
29.05. | Taysha-Aktie steigt nach positiver Studienplanung und FDA-Abstimmung | 2 | Investing.com Deutsch | ||
29.05. | Taysha stock surges on positive trial design and FDA alignment | 1 | Investing.com | ||
29.05. | JMP raises Taysha stock target to $6 on positive FDA alignment | 2 | Investing.com | ||
29.05. | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
28.05. | Taysha Gene Therapies, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
28.05. | Taysha Gene Therapies commences underwritten public offering | 4 | Seeking Alpha | ||
28.05. | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent ... | 180 | GlobeNewswire (Europe) | Natural history data analysis established patients = six years of age are in developmental plateau, with a ~0% likelihood of gaining/regaining developmental milestones across the core functional domains... ► Artikel lesen | |
28.05. | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
15.05. | Baird maintains Outperform on Taysha stock, reiterates $7 target | 1 | Investing.com | ||
15.05. | Taysha outlines expedited pivotal trial start for TSHA-102 following FDA alignment | 2 | Seeking Alpha | ||
15.05. | Taysha Gene Therapies, Inc. Q1 Loss Decreases, Beats Estimates | 1 | RTTNews |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
CUREVAC | 3,830 | -0,83 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
AMGEN | 254,90 | +0,08 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
NOVAVAX | 6,520 | -0,20 % | Aktien New York: Rücksetzer nach US-Bonitätsabstufung verpufft | NEW YORK (dpa-AFX) - Die Abstufung der US-Kreditwürdigkeit durch Moody?s hat die Anleger in New York am Montag nicht lange beeindruckt. Benoit Anne, Anleiheexperte bei MFS Investment Management, verwies... ► Artikel lesen | |
BIOGEN | 116,70 | -0,09 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
INOVIO PHARMACEUTICALS | 1,980 | -0,50 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
MAINZ BIOMED | 2,775 | -100,00 % | MAINZ BIOMED N.V. - 6-K, Report of foreign issuer | ||
VIKING THERAPEUTICS | 24,220 | -0,78 % | Viking Therapeutics auf Jefferies-Konferenz: Vielversprechendes Abnehm-Medikament | ||
INTELLIA THERAPEUTICS | 7,146 | +0,37 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,524 | -0,38 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 9,668 | -0,17 % | BioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland... ► Artikel lesen | |
KUROS BIOSCIENCES | 26,300 | -0,23 % | Kuros Biosciences AG: Kuros Biosciences to share latest MagnetOs market impact and strategic priorities at Capital Market Day in Zürich | Kuros Biosciences to share latest MagnetOs market impact and strategic priorities at Capital Markets Day in Zürich
Schlieren (Zürich), Switzerland, May 13, 2025 - Kuros Biosciences ("Kuros"... ► Artikel lesen | |
TEMPUS AI | 54,74 | +0,51 % | Opening Bell: Constellation Energy, Vistra, Netflix, Applied Digital, Steel Dyn., Pony.ai, Tempus AI | Zum Wochenauftakt schwankten die US-Börsen zwischen neuen Zolldrohungen und der Hoffnung auf sinkende Zinsen. Zwar sorgte US-Präsident Trumps verschärfte Rhetorik im Handelsstreit mit China zunächst... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 38,180 | +1,17 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen |